ChemMedChem

Cover image for Vol. 1 Issue 9

September 11, 2006

Volume 1, Issue 9

Pages 909–1030

  1. Cover Picture

    1. Top of page
    2. Cover Picture
    3. Graphical Abstract
    4. News
    5. Review
    6. Minireview
    7. Highlight
    8. Communications
    9. Full Papers
    10. Preview
    1. Cover Picture: Synthesis and Biological Evaluation of a Multiantigenic Tn/TF-Containing Glycopeptide Mimic of the Tumor-Related MUC1 Glycoprotein (ChemMedChem 9/2006) (page 909)

      Gaëlle-Anne Cremer, Nicole Bureaud, Véronique Piller, Horst Kunz, Friedrich Piller and Agnès F. Delmas

      Article first published online: 1 SEP 2006 | DOI: 10.1002/cmdc.200690032

      The cover picture shows human MCF7 mammary adenocarcinoma cells, a cell line which has been used extensively to characterize tumor-associated MUC1 glycoprotein. Cells were analysed by fluorescence-activated cell sorting after being labelled with antibodies induced in mice by a synthetic glycopeptide construct (structure shown) in association with a mild adjuvant suitable for human therapy. This construct, composed of a universal T-helper and three diversely glycosylated tumor-related epitopes, was assembled using a convergent strategy based on two successive oxime ligations. It is the most immunogenic synthetic construct reported to date and is able to elicit antibodies that recognize tumor-related MUC1 on MCF7 cells. (Thanks to T. Cantalupo for the image.) For more details, see the Communication by A. F. Delmas et al. on p. 965 ff.

  2. Graphical Abstract

    1. Top of page
    2. Cover Picture
    3. Graphical Abstract
    4. News
    5. Review
    6. Minireview
    7. Highlight
    8. Communications
    9. Full Papers
    10. Preview
    1. Graphical Abstract: ChemMedChem 9/2006 (pages 911–915)

      Article first published online: 1 SEP 2006 | DOI: 10.1002/cmdc.200690033

  3. News

    1. Top of page
    2. Cover Picture
    3. Graphical Abstract
    4. News
    5. Review
    6. Minireview
    7. Highlight
    8. Communications
    9. Full Papers
    10. Preview
    1. From our sister journals: ChemMedChem 9/2006 (pages 916–917)

      Article first published online: 1 SEP 2006 | DOI: 10.1002/cmdc.200690034

  4. Review

    1. Top of page
    2. Cover Picture
    3. Graphical Abstract
    4. News
    5. Review
    6. Minireview
    7. Highlight
    8. Communications
    9. Full Papers
    10. Preview
    1. Prediction of ADMET Properties (pages 920–937)

      Ulf Norinder and Christel A. S. Bergström

      Article first published online: 1 SEP 2006 | DOI: 10.1002/cmdc.200600155

      Thumbnail image of graphical abstract

      The power of prediction: Herein some of the approaches and techniques used today to derive in silico models for the prediction of ADMET properties are described. This Review also discusses some of the fundamental requirements for deriving statistically sound and predictive ADMET relationships as well as some of the pitfalls and problems encountered during these investigations.

  5. Minireview

    1. Top of page
    2. Cover Picture
    3. Graphical Abstract
    4. News
    5. Review
    6. Minireview
    7. Highlight
    8. Communications
    9. Full Papers
    10. Preview
    1. Bis-Tetrahydrofuran: a Privileged Ligand for Darunavir and a New Generation of HIV Protease Inhibitors That Combat Drug Resistance (pages 939–950)

      Arun K. Ghosh, Perali Ramu Sridhar, Nagaswamy Kumaragurubaran, Yasuhiro Koh, Irene T. Weber and Hiroaki Mitsuya

      Article first published online: 22 AUG 2006 | DOI: 10.1002/cmdc.200600103

      Thumbnail image of graphical abstract

      Two inhibitors that incorporate bis-THF as an effective high-affinity P2 ligand for the HIV-1 protease substrate binding site maintain impressive potency against mutant strains resistant to currently approved protease inhibitors. Crystallographic structures of protein–ligand complexes help to explain the superior antiviral property of these inhibitors and their potency against a wide spectrum of HIV-1 strains.

  6. Highlight

    1. Top of page
    2. Cover Picture
    3. Graphical Abstract
    4. News
    5. Review
    6. Minireview
    7. Highlight
    8. Communications
    9. Full Papers
    10. Preview
    1. Platensimycin, a New Antibiotic and “Superbug Challenger” from Nature (pages 951–954)

      Dieter Häbich and Franz von Nussbaum

      Article first published online: 3 AUG 2006 | DOI: 10.1002/cmdc.200600145

      Thumbnail image of graphical abstract

      Natural products have once again proven their value as guideposts for unexplored targets. “Old-fashioned” extract screening integrated into an innovative assay set-up has opened a new playground for medicinal chemists. Platensimycin is the first member of a novel class of antibiotics that acts through a clinically unexploited target.

  7. Communications

    1. Top of page
    2. Cover Picture
    3. Graphical Abstract
    4. News
    5. Review
    6. Minireview
    7. Highlight
    8. Communications
    9. Full Papers
    10. Preview
    1. Identification of a Potent Agonist of the Orphan Nuclear Receptor Nurr1 (pages 955–958)

      Celine Dubois, Bastian Hengerer and Henri Mattes

      Article first published online: 26 JUL 2006 | DOI: 10.1002/cmdc.200600078

      Thumbnail image of graphical abstract

      Benzimidazole-based Nurr1 agonists: Combinatorial chemistry and structure-based design were joined together to produce a lead-finding library of compounds focused on the nuclear receptor target family. A second-generation library directed against Nurr1, a specific orphan member of this family, was also prepared. This protocol allowed the discovery of a Nurr1 agonist with an EC50 value of 8 nM.

    2. Correlation of Biological Activity with Active Site Binding Modes of Geminal Disulfone HIV-1 Integrase Inhibitors (pages 959–964)

      D. Christopher Meadows, Dean J. Tantillo and Jacquelyn Gervay-Hague

      Article first published online: 26 JUL 2006 | DOI: 10.1002/cmdc.200600040

      Thumbnail image of graphical abstract

      Binding modes of a series of potent geminal disulfone-containing HIV-1 integrase inhibitors were investigated using AutoDock 3.0. Two major conformations were shared for this series of compounds: a “U-shaped” conformation and an “L-shaped” conformation. The data presented suggest that the U-shaped conformer may be the more biologically relevant conformation and that the design of molecules that are structurally biased in that conformation could lead to more potent analogues.

    3. Synthesis and Biological Evaluation of a Multiantigenic Tn/TF-Containing Glycopeptide Mimic of the Tumor-Related MUC1 Glycoprotein (pages 965–968)

      Gaëlle-Anne Cremer, Nicole Bureaud, Véronique Piller, Horst Kunz, Friedrich Piller and Agnès F. Delmas

      Article first published online: 21 JUL 2006 | DOI: 10.1002/cmdc.200600104

      Thumbnail image of graphical abstract

      The glycopeptide construct shown was synthesized using a convergent strategy based on oxime chemical ligation. It is composed of a universal T-helper and three tumor-related epitopes from the human mucin MUC1, an nonglycosylated repeat unit, and two units glycosylated with the Tn and TF epitopes, respectively. In association with a mild adjuvant suitable for human therapy, this construct elicited a strong specific immune response in mice, directed against natural tumor-associated structures.

    4. Probing, Inhibition, and Crystallographic Characterization of Metallo-β-lactamase (IMP-1) with Fluorescent Agents Containing Dansyl and Thiol Groups (pages 969–972)

      Hiromasa Kurosaki, Yoshihiro Yamaguchi, Hisami Yasuzawa, Wanchun Jin, Yuriko Yamagata and Yoshichika Arakawa

      Article first published online: 28 AUG 2006 | DOI: 10.1002/cmdc.200600115

      Thumbnail image of graphical abstract

      A series of fluorescent probes, N-(5-(dimethylamino)-1-naphthalenesulfonamido(alkyl)n)-3-thiopropionamide (DansylCnSHs), were rationally designed to detect and inhibit metallo-β-lactamase (IMP-1). These compounds were shown to function as fluorescent probes for and inhibitors of metallo-β-lactamases. The X-ray crystallographic structure shown indicates the potential of these agents for use as a new fluorescent probes for metallo-β-lactamases.

  8. Full Papers

    1. Top of page
    2. Cover Picture
    3. Graphical Abstract
    4. News
    5. Review
    6. Minireview
    7. Highlight
    8. Communications
    9. Full Papers
    10. Preview
    1. Ligand-Based Virtual Screening, Parallel Solution-Phase and Microwave-Assisted Synthesis as Tools to Identify and Synthesize New Inhibitors of Mycobacterium tuberculosis (pages 973–989)

      Fabrizio Manetti, Matteo Magnani, Daniele Castagnolo, Laura Passalacqua, Maurizio Botta, Federico Corelli, Manuela Saddi, Delia Deidda and Alessandro De Logu

      Article first published online: 7 AUG 2006 | DOI: 10.1002/cmdc.200600026

      Thumbnail image of graphical abstract

      Step by step: Ligand-based virtual screening was applied toward the identification of new compounds targeting Mycobacterium tuberculosis. After generating a large virtual library, a realistic number of hits was selected through a series of filtering steps, leading to the identification of two leads. These were used to synthesize a small series of analogues.

    2. Determination of the Bound Conformation of a Competitive Nanomolar Inhibitor of Mycobacterium tuberculosis Type II Dehydroquinase by NMR Spectroscopy (pages 990–996)

      Verónica F. V. Prazeres, Cristina Sánchez-Sixto, Luis Castedo, Ángeles Canales, Francisco Javier Cañada, Jesús Jiménez-Barbero, Heather Lamb, Alastair R. Hawkins and Concepción González-Bello

      Article first published online: 3 AUG 2006 | DOI: 10.1002/cmdc.200600100

      Thumbnail image of graphical abstract

      Saturation transfer difference (STD) and transferred NOESY experiments were carried out to deduce the bound conformation of a nanomolar inhibitor of M. tuberculosis type II dehydroquinase, the third enzyme of the shikimic acid pathway. One conformation of those present in solution for the competitive 3-nitrophenyl derivative inhibitor is selected when it is bound to the active site of the enzyme.

    3. Conformationally Constrained CCK8 Analogues Obtained from a Rationally Designed Peptide Library as Ligands for Cholecystokinin Type B Receptor (pages 997–1006)

      Stefania De Luca, Michele Saviano, Raffaella Della Moglie, Giuseppe Digilio, Chiara Bracco, Luigi Aloj, Laura Tarallo, Carlo Pedone and Giancarlo Morelli

      Article first published online: 17 AUG 2006 | DOI: 10.1002/cmdc.200600054

      Thumbnail image of graphical abstract

      A rationally designed peptide library provided CCK8 analogues as new ligands (in red) for the cholecystokinin type B receptor (blue). In vitro cellular assays were used to determine the binding affinity of the ligands, and IC50≈10 μM for the best compounds. NMR structural data of the lead compound confirm that the structure is stabilized by both the cyclic constraint and by interaction with the micelle.

    4. Structure–Activity Relationship Studies on the Immune Stimulatory Effects of Base-Modified CpG Toll-Like Receptor 9 Agonists (pages 1007–1014)

      Marion Jurk, Andrea Kritzler, Harald Debelak, Jörg Vollmer, Arthur M. Krieg and Eugen Uhlmann

      Article first published online: 3 AUG 2006 | DOI: 10.1002/cmdc.200600064

      Thumbnail image of graphical abstract

      Activation of Toll-like receptors (TLRs) results in stimulation of the innate immune response, including secretion of proinflammatory cytokines, up-regulation of co-stimulatory molecules, and secretion of cytokines and chemokines. In our SAR model, the CpG dinucleotide motif of immune stimulatory oligodeoxynucleotides is recognized by TLR9 by the Hoogsteen site of guanine and the C5 corner of cytosine resulting in potent stimulation of the innate immune response.

    5. Use of Triplet Excited States for the Study of Drug Binding to Human and Bovine Serum Albumins (pages 1015–1020)

      Ignacio Vayá, Carlos J. Bueno, M. Consuelo Jiménez and Miguel A. Miranda

      Article first published online: 11 AUG 2006 | DOI: 10.1002/cmdc.200600061

      Thumbnail image of graphical abstract

      The triplet excited states of (S)- and (R)-flurbiprofen (FBP) were used as reporters for the microenvironments of the binding sites of serum albumins. Multiexponential fitting of the triplet decays (λ=360 nm) can be satisfactorily correlated with the distribution of the drug among the two protein binding sites and the bulk solution. Triplet lifetimes and site occupancy are both sensitive to the type of serum albumin used.

    6. Rational Design of Aziridine-Containing Cysteine Protease Inhibitors with Improved Potency: Studies on Inhibition Mechanism (pages 1021–1028)

      Radim Vicik, Holger Helten, Tanja Schirmeister and Bernd Engels

      Article first published online: 10 JUL 2006 | DOI: 10.1002/cmdc.200600081

      Thumbnail image of graphical abstract

      Cysteine proteases are attractive targets for the development of new drugs, as they play pivotal roles in many diseases. Aziridine-containing cysteine protease inhibitors have been developed. To investigate the influence of the aziridine ring substituents on the kinetics and thermodynamics of the ring-opening reaction in detail, quantum chemical computations were performed. N-formylated aziridine was predicted to be much more effective than the nonformylated system.

  9. Preview

    1. Top of page
    2. Cover Picture
    3. Graphical Abstract
    4. News
    5. Review
    6. Minireview
    7. Highlight
    8. Communications
    9. Full Papers
    10. Preview
    1. You have free access to this content
      Preview: ChemMedChem 9/2006 (page 1030)

      Article first published online: 1 SEP 2006 | DOI: 10.1002/cmdc.200690031

SEARCH

SEARCH BY CITATION